Boston Scientific charts stent growth in India

India is apparently becoming a more relevant market for stents that release drugs to treat heart disease. Boston Scientific, the Natick, MA-based device giant, says it has begun sales of its Promus Element Everolimus-Eluting Coronary Stent and its Taxus Element Paclitaxel-Eluting Coronary Stent in India. There are an estimated 150,000 drug-eluting coronary stents implanted in India annually, making the country one of the most rapidly growing markets in the world for the drug-device combination products, according to Boston Scientific. “A key component of our growth strategy involves expanding our footprint in emerging markets like India, where we are making significant investments in sales, distribution and clinical infrastructure," said Ray Elliott, president and chief executive officer of Boston Scientific, in a statement. Boston Scientific release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.